Literature DB >> 3481541

Activity of cefmetazole against anaerobic bacteria.

N A Cornick1, N V Jacobus, S L Gorbach.   

Abstract

The in vitro activity of cefmetazole versus that of other antimicrobial drugs was assessed against 374 clinical isolates of Bacteroides spp., Clostridium spp., and anaerobic gram-positive cocci. Compared with cefoxitin, cefmetazole showed good activity against Bacteroides fragilis, other Bacteroides species, and anaerobic cocci. It was somewhat less active than cefoxitin against Bacteroides thetaiotaomicron, B. ovatus, B. distasonis, and B. vulgatus and somewhat more active against Clostridium spp.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3481541      PMCID： PMC175846          DOI： 10.1128/AAC.31.12.2010

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  Antimicrobial activity of cefmetazole (CS-1170) and recommendations for susceptibility testing by disk diffusion, dilution, and anaerobic methods.

Authors:  R N Jones; A L Barry; P C Fuchs; C Thornsberry
Journal:  J Clin Microbiol       Date:  1986-12       Impact factor: 5.948

2.  Susceptibility of anaerobes to cefoxitin and other cephalosporins.

Authors:  F P Tally; N V Jacobus; J G Bartlett; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1975-02       Impact factor: 5.191

3.  Comparative antibacterial activities of 7 alpha-methoxy cephalosporins and 7 beta-methoxyiminoacetamido cephalosporins against Bacteroides fragilis.

Authors:  T Kesado; K Watanabe; Y Asahi; M Isono; K Ueno
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

4.  Susceptibility of the Bacteroides fragilis group in the United States in 1981.

Authors:  F P Tally; G J Cuchural; N V Jacobus; S L Gorbach; K E Aldridge; T J Cleary; S M Finegold; G B Hill; P B Iannini; R V McCloskey; J P O'Keefe; C L Pierson
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

5.  Susceptibility of anaerobic bacteria to 23 antimicrobial agents.

Authors:  V L Sutter; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

6.  In vitro activity of cefbuperazone compared with that of other new beta-lactam agents against anaerobic gram-negative bacilli and contribution of beta-lactamase to resistance.

Authors:  V E Del Bene; P J Carek; J A Twitty; L J Burkey
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

7.  Comparison of the activities of penicillin G and new beta-lactam antibiotics against clinical isolates of Bacteroides species.

Authors:  K E Aldridge; C V Sanders; A Janney; S Faro; R L Marier
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

8.  In vitro activity of cefbuperazone against Bacteroides spp.

Authors:  M B Dias; N V Jacobus; S L Gorbach; F P Tally
Journal:  Antimicrob Agents Chemother       Date:  1985-06       Impact factor: 5.191

9.  In vitro activity of azthreonam, a monobactam antibiotic.

Authors:  N V Jacobus; M C Ferreira; M Barza
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191
  9 in total
  3 in total

1.  Disposition of cefmetazole in healthy volunteers and patients with impaired renal function.

Authors:  C E Halstenson; D R Guay; J A Opsahl; C A Hirata; L S Olanoff; E Novak; H Ko; K S Cathcart; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

2.  Use of cephalosporins for prophylaxis and therapy of polymicrobial infection in mice.

Authors:  I Brook
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

3.  Annual incidence, epidemiology, and comparative in vitro susceptibilities to cefoxitin, cefotetan, cefmetazole, and ceftizoxime of recent community-acquired isolates of the Bacteroides fragilis group.

Authors:  E J Goldstein; D M Citron
Journal:  J Clin Microbiol       Date:  1988-11       Impact factor: 5.948
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.